High response rate to PD-1 blockade in desmoplastic melanomas. (Q50103620)

22 July 2018

title

High response rate to PD-1 blockade in desmoplastic melanomas. (English)

1 reference

22 July 2018

12

Bartosz Chmielowski

1 reference

22 July 2018

25

Antoni Ribas

1 reference

PMCID

5773412

22 July 2018

Pier Federico Gherardini

11

object named as

Pier Federico Gherardini

1 reference

22 July 2018

22

Jane Messina

1 reference

22 July 2018

24

Georgina V Long

1 reference

22 July 2018

Siwen Hu-Lieskovan

3

object named as

Siwen Hu-Lieskovan

1 reference

22 July 2018

Richard Scolyer

21

object named as

Richard A Scolyer

1 reference

22 July 2018

author name string

Zeynep Eroglu

1

1 reference

22 July 2018

Jesse M Zaretsky

2

1 reference

22 July 2018

Dae Won Kim

4

1 reference

22 July 2018

Alain Algazi

5

1 reference

22 July 2018

Douglas B Johnson

6

1 reference

22 July 2018

Elizabeth Liniker

7

1 reference

22 July 2018

Ben Kong

8

1 reference

22 July 2018

Rodrigo Munhoz

9

1 reference

22 July 2018

Suthee Rapisuwon

10

1 reference

22 July 2018

Xiaoyan Wang

13

1 reference

22 July 2018

I Peter Shintaku

14

1 reference

22 July 2018

Cody Wei

15

1 reference

22 July 2018

Jeffrey A Sosman

16

1 reference

22 July 2018

Richard W Joseph

17

1 reference

22 July 2018

Michael A Postow

18

1 reference

22 July 2018

Matteo S Carlino

19

1 reference

22 July 2018

Wen-Jen Hwu

20

1 reference

22 July 2018

Alistair J Cochran

23

1 reference

22 July 2018

language of work or name

English

0 references

publication date

10 January 2018

1 reference

22 July 2018

published in

Nature

1 reference

22 July 2018

volume

553

1 reference

22 July 2018

issue

7688

1 reference

22 July 2018

page(s)

347-350

1 reference

22 July 2018

https://scigraph.springernature.com/pub.10.1038/nature25187

exact match

0 references

cites work

Whole-genome landscapes of major melanoma subtypes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

MYC regulates the antitumor immune response through CD47 and PD-L1

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Genomic Classification of Cutaneous Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

NF1 Mutations Are Common in Desmoplastic Melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Clinicopathologic predictors of survival in patients with desmoplastic melanoma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

PD-1 blockade induces responses by inhibiting adaptive immune resistance

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Signatures of mutational processes in human cancer

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

The blockade of immune checkpoints in cancer immunotherapy

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5773412

Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors

14 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE25187

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NATURE25187

1 reference

22 July 2018

PMCID

5773412

1 reference

22 July 2018

PubMed ID

29320474

1 reference

22 July 2018